> top > docs > PubMed:11485127 > annotations

PubMed:11485127 JSONTXT

Annnotations TAB JSON ListView MergeView

disease_gene_microbe_small

Id Subject Object Predicate Lexical cue
T0 45-71 DOID:0050589 denotes inflammatory bowel disease
T1 225-240 DOID:8778 denotes rohn's disease
T2 250-268 DOID:8577 denotes lcerative colitis
T3 1059-1070 DOID:381 denotes rthropathy,
T4 1393-1397 DOID:0050486 denotes ash
T5 1544-1560 DOID:813 denotes eptic arthritis
T6 1573-1586 DOID:1019 denotes steomyelitis
T7 1499-1520 taxonomy:1280 denotes taphylococcus aureus

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-72 Sentence denotes Use of infliximab in pediatric patients with inflammatory bowel disease.
T2 73-84 Sentence denotes BACKGROUND:
T3 85-273 Sentence denotes The concentration of tumor necrosis factor, a proinflammatory cytokine, is increased in the gastrointestinal mucosa of patents with active Crohn's disease (CD) and ulcerative colitis (UC).
T4 274-376 Sentence denotes Neutralization of tumor necrosis factor decreases the mucosal inflammatory response of adults with CD.
T5 377-523 Sentence denotes Little information is available on the use of monoclonal antibody to tumor necrosis factor (infliximab) in children and adolescents with CD or UC.
T6 524-534 Sentence denotes OBJECTIVE:
T7 535-612 Sentence denotes To evaluate the clinical response and side effects of patients to infliximab.
T8 613-621 Sentence denotes METHODS:
T9 622-783 Sentence denotes A retrospective review of data regarding 18 pediatric and adolescent patients with active CD (n = 15) and UC (n = 3) poorly controlled with conventional therapy.
T10 784-902 Sentence denotes All patients received one to six intravenous infusions of infliximab 5 mg/kg, while receiving their usual medications.
T11 903-911 Sentence denotes RESULTS:
T12 912-1136 Sentence denotes All patients experienced clinical improvement, including decrease in the frequency of stooling and resolution of extraintestinal symptoms such as arthropathy, malaise, and skin manifestations after treatment with infliximab.
T13 1137-1221 Sentence denotes All but one patient had a documented decrease in the erythrocyte sedimentation rate.
T14 1222-1312 Sentence denotes Prednisone dosage was tapered in all but two patients, and discontinued in seven patients.
T15 1313-1367 Sentence denotes Intravenous infusion of infliximab was well tolerated.
T16 1368-1429 Sentence denotes One patient developed a rash several days after the infusion.
T17 1430-1671 Sentence denotes A patient who received six infliximab infusions developed recurrent Staphylococcus aureus infections, as well as septic arthritis and chronic osteomyelitis during the follow-up period, raising the issue of the long-term safety of infliximab.
T18 1672-1684 Sentence denotes CONCLUSIONS:
T19 1685-1805 Sentence denotes Treatment of our patients with refractory CD and UC with infliximab was associated with remarkable clinical improvement.
T20 1806-1934 Sentence denotes Although the drug may have an important role in their management, further assessment of long-term safety and efficacy is needed.
T1 0-72 Sentence denotes Use of infliximab in pediatric patients with inflammatory bowel disease.
T2 73-84 Sentence denotes BACKGROUND:
T3 85-273 Sentence denotes The concentration of tumor necrosis factor, a proinflammatory cytokine, is increased in the gastrointestinal mucosa of patents with active Crohn's disease (CD) and ulcerative colitis (UC).
T4 274-376 Sentence denotes Neutralization of tumor necrosis factor decreases the mucosal inflammatory response of adults with CD.
T5 377-523 Sentence denotes Little information is available on the use of monoclonal antibody to tumor necrosis factor (infliximab) in children and adolescents with CD or UC.
T6 524-534 Sentence denotes OBJECTIVE:
T7 535-612 Sentence denotes To evaluate the clinical response and side effects of patients to infliximab.
T8 613-621 Sentence denotes METHODS:
T9 622-783 Sentence denotes A retrospective review of data regarding 18 pediatric and adolescent patients with active CD (n = 15) and UC (n = 3) poorly controlled with conventional therapy.
T10 784-902 Sentence denotes All patients received one to six intravenous infusions of infliximab 5 mg/kg, while receiving their usual medications.
T11 903-911 Sentence denotes RESULTS:
T12 912-1136 Sentence denotes All patients experienced clinical improvement, including decrease in the frequency of stooling and resolution of extraintestinal symptoms such as arthropathy, malaise, and skin manifestations after treatment with infliximab.
T13 1137-1221 Sentence denotes All but one patient had a documented decrease in the erythrocyte sedimentation rate.
T14 1222-1312 Sentence denotes Prednisone dosage was tapered in all but two patients, and discontinued in seven patients.
T15 1313-1367 Sentence denotes Intravenous infusion of infliximab was well tolerated.
T16 1368-1429 Sentence denotes One patient developed a rash several days after the infusion.
T17 1430-1671 Sentence denotes A patient who received six infliximab infusions developed recurrent Staphylococcus aureus infections, as well as septic arthritis and chronic osteomyelitis during the follow-up period, raising the issue of the long-term safety of infliximab.
T18 1672-1684 Sentence denotes CONCLUSIONS:
T19 1685-1805 Sentence denotes Treatment of our patients with refractory CD and UC with infliximab was associated with remarkable clinical improvement.
T20 1806-1934 Sentence denotes Although the drug may have an important role in their management, further assessment of long-term safety and efficacy is needed.